Saturday 17 October 2026
Export XBIT’s income statement to Excel — free account
XBiotech Inc.
XBIT Healthcare Biotechnology
XBiotech Inc.’s revenue for fiscal 2022 (year ended December 2022) was $4.0 million. In the quarter to June 2026, EPS fell 266.7% and free cash flow grew 25.3%, each against the same quarter a year earlier.
2.12
0.04
−1.85%
Follow XBIT
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | 3 | — | — | — |
P/E ratio |
— | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
P/S ratio |
— | — | — | — | 10.96 | 18.18 | 25.66 | — | — | — |
Altman Z-Score |
— | — | — | — | 58.13 | 35.49 | 11.69 | — | — | — |
P/FCF ratio |
— | — | — | — | 0.00 | 5.07 | 0.00 | — | — | — |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | 78.23 | 54.09 | 48.72 | — | — | — |
Beneish M-Score |
— | — | — | — | — | (6.02) | (4.17) | — | — | — |
P/Operating CF |
— | — | — | — | (1,233.71) | (190.10) | (32.52) | — | — | — |
P/B ratio |
— | — | — | — | 1.38 | 1.24 | 0.43 | — | — | — |
Price to Tangible BV |
— | — | — | — | 1.38 | 1.24 | 0.43 | — | — | — |
EV/Sales |
— | — | — | — | 5.57 | 5.30 | (28.58) | — | — | — |
EV/EBITDA |
— | — | — | — | 0.00 | 0.00 | 3.60 | — | — | — |
EV/Operating CF |
— | — | — | — | (3.76) | 1.40 | 7.73 | — | — | — |
EV/FCF |
— | — | — | — | (3.56) | 1.48 | 7.44 | — | — | — |
Quick Ratio |
4.31 | 11.38 | 5.37 | 11.87 | 81.10 | 71.22 | 53.92 | 32.94 | 11.49 | 15.88 |
Current Ratio |
4.64 | 11.94 | 5.78 | 11.90 | 81.80 | 71.49 | 54.07 | 33.07 | 11.56 | 16.01 |
Net Debt/EBITDA |
0.66 | 0.98 | 0.85 | 24.75 | 14.80 | 10.56 | 6.82 | 5.59 | 3.99 | 2.33 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 5.15% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.06 | 0.02 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.87 | 1.02 | 0.78 | (0.03) | 5.81 | (3.99) | 0.45 | 0.76 | 0.80 | 0.88 |
Capex/Depreciation |
(19.93) | (0.95) | (0.05) | (0.09) | (1.67) | (1.33) | (0.22) | (0.21) | (0.75) | (0.17) |
Interest Coverage |
(1,076.80) | (96.21) | (52.48) | (55.38) | (7.44) | (53.71) | (9.02) | — | (52.63) | (632.78) |
| (65.09%) | (55.61%) | (41.63%) | 167.78% | (2.03%) | (5.64%) | (12.91%) | (10.69%) | (19.21%) | (28.23%) | |
| (59.82%) | (50.99%) | (39.39%) | 155.27% | (1.92%) | (5.54%) | (12.62%) | (10.39%) | (18.10%) | (26.08%) | |
ROIC |
(133.29%) | (74.97%) | (51.30%) | (47.57%) | (10.27%) | (48.38%) | (94.03%) | (124.55%) | (133.79%) | (235.17%) |
Return on Tangible Assets |
(134.91%) | (55.08%) | (51.06%) | 98.15% | (3.21%) | (6.41%) | (13.59%) | (11.14%) | (20.94%) | (32.04%) |
Average Days of Receivables |
— | — | — | — | 711.38 | 177.66 | 160.56 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 21.65% | 153.68% | 786.63% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 41.36% | 51.04% | 157.23% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 28.60% | 24.26% | 126.23% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | — | — | — | 0.67 | 0.72 | 2.08 | — | — | — |
Graham Number |
— | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
Earnings Yield |
— | — | — | — | (2.49%) | (5.21%) | (31.95%) | — | — | — |
Free Cash Flow Yield |
— | — | — | — | (14.28%) | 19.71% | (14.98%) | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 1.43 | 0.61 | 0.13 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.42) | (0.96) | (0.46) | (0.47) | (2.11) | 2.31 | (0.49) | (0.62) | (1.02) | (1.31) |
Capex per Share |
(0.43) | (0.04) | 0.00 | (0.01) | (0.12) | (0.12) | (0.02) | (0.01) | (0.04) | (0.01) |
Free Cash Flow per Share |
(1.85) | (1.01) | (0.47) | (0.47) | (2.23) | 2.19 | (0.51) | (0.63) | (1.06) | (1.32) |
Cash per Share |
1.06 | 0.91 | 0.44 | 18.35 | 7.70 | 7.89 | 7.14 | 6.57 | 5.67 | 4.12 |
Shareholders Equity per Share |
1.82 | 1.73 | 1.16 | 19.40 | 11.31 | 8.97 | 7.90 | 7.19 | 5.98 | 4.60 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.82 | 1.73 | 1.16 | 19.40 | 11.31 | 8.97 | 7.90 | 7.19 | 5.98 | 4.60 |
Free Cash Flow |
(59.93) | (35.05) | (16.66) | (18.47) | (68.88) | 65.92 | (15.41) | (19.09) | (32.27) | (40.21) |
Working Capital |
28.97 | 30.54 | 14.07 | 656.07 | 321.89 | 243.42 | 215.78 | 195.62 | 159.46 | 119.02 |
Capital Expenditures |
(13.91) | (1.40) | (0.12) | (0.20) | (3.73) | (3.52) | (0.58) | (0.36) | (1.30) | (0.29) |
Net Current Asset Value |
28.94 | 30.52 | 14.07 | 655.02 | 320.77 | 241.08 | 214.14 | 193.95 | 157.74 | 117.22 |
EV/EBIT |
— | — | — | — | 0.00 | 0.00 | 3.32 | — | — | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.19 | 0.15 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.07 | 0.05 | 0.09 | 0.09 | 0.08 | 0.09 | 0.10 | 0.07 | 0.07 | 0.07 |
Cash ROIC |
(64.17%) | (38.13%) | (29.11%) | (1.26%) | (11.75%) | 13.02% | (3.37%) | (4.56%) | (8.84%) | (15.12%) |
Accounts Receivable Turnover |
— | — | — | — | 0.93 | 0.39 | 0.75 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.15 | 0.48 | 1.44 | 1.24 | 14.89 | 2.55 | 0.29 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
2,317.07 | 425.51 | 247.98 | 332.23 | 26.32 | 129.76 | 1,350.11 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | — | — | — | 47.35 | 47.35 | 5.36 | 1.35 | 0.90 | 0.61 |
Average Payables |
4.63 | 3.08 | 1.69 | 1.90 | 2.32 | 2.28 | 2.24 | 2.46 | 2.37 | 1.88 |
Average Assets |
88.20 | 65.01 | 53.66 | 430.61 | 585.31 | 314.46 | 260.64 | 236.36 | 212.85 | 174.59 |
Average Common Equity |
81.06 | 59.61 | 50.78 | 398.51 | 552.14 | 309.01 | 254.89 | 229.62 | 200.56 | 161.31 |
Columns are period end dates